Idaho is currently home to 368 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boise, Meridian, Idaho Falls and Nampa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia
NCT05745883
Recruiting
This Phase 1b study of DISC-0974 will assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult participants with Non-Dialysis Dependent Chronic Kidney Disease and Anemia.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/29/2024
Locations: Boise Kidney & Hypertension PLLC, Nampa, Idaho
Conditions: Chronic Kidney Diseases, Anemia of Chronic Kidney Disease
Register for Updates
M6®-C Artificial Cervical Disc Two-Level IDE Pivotal Study
NCT04982835
Recruiting
Prospective, concurrently controlled, multi-center study to evaluate the safety and effectiveness of the Spinal Kinetics M6-C™ artificial cervical disc compared to anterior cervical discectomy and fusion (ACDF) for the treatment of contiguous two-level symptomatic cervical radiculopathy at vertebral levels from C3 to C7 with or without spinal cord compression.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/22/2024
Locations: Axis Spine, Coeur d'Alene, Idaho
Conditions: Cervical Disc Degenerative Disorder
Register for Updates
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
NCT04960709
Recruiting
A global phase 3, multicenter, randomized, trial, to Determine the Efficacy and Safety of Durvalumab in combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in combination with Enfortumab vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or who refuse Cisplantin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer. The goal of the study is to explore the triplet combination of Durvalumab, Tremelimumab and Enfortumab Vedotin in terms of efficacy a... Read More
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
03/21/2024
Locations: Research Site, Coeur d'Alene, Idaho
Conditions: Muscle Invasive Bladder Cancer
Register for Updates
Pediatric Obesity Weight Evaluation Registry (POWER) Study
NCT02121132
Recruiting
The main objective of this study is to establish a national pediatric obesity registry known as POWER (Pediatric Obesity Weight Evaluation Registry). This registry will contain clinical data from individual comprehensive pediatric weight management programs around the United States for overweight and obese youth.
Gender:
All
Ages:
18 years and below
Trial Updated:
03/21/2024
Locations: St. Luke's Children's Hospital, Boise, Idaho
Conditions: Overweight, Obesity
Register for Updates
Post-Market Feasibility Study of the Tenon Medical CATAMARAN™ SI Joint Fusion System
NCT05633888
Recruiting
The purpose of this study is to evaluate the outcomes of patients with sacroiliac joint pain treated with the CATAMARAN SI Joint Fusion System.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/18/2024
Locations: Northwest Specialty Hospital, Coeur d'Alene, Idaho
Conditions: Sacroiliac Joint Disruption, Degenerative Sacroiliitis
Register for Updates
Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment
NCT05455606
Recruiting
This clinical trial studies how well an educationally enhanced genomic tumor board (EGTB) intervention works to increase the number of patients with solid tumors that have come back (recurrent), do not respond to treatment (refractory), have spread to other parts of the body (metastatic), or are newly diagnosed and spread to other parts of the body (advanced) who receive genome-informed treatment. Genome-informed treatment refers to treatment based on the information found in genomic tumor test... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho
Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Register for Updates
Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers
NCT06252285
Recruiting
This study is a phase III, randomized, observer-blind, placebo-controlled, multinational, multi-center study to be conducted in approximately 6300 children 6 months to < 22 months of age. The purpose of the study is to evaluate the efficacy, immunogenicity, and safety of Respiratory Syncytial Virus Toddler (RSVt) vaccine administered by intranasal route compared to placebo. Eligible participants will be randomized in a 1:1 ratio to receive 2 intranasal administrations of either the RSVt vaccine... Read More
Gender:
All
Ages:
Between 6 months and 21 months
Trial Updated:
03/15/2024
Locations: Snake River Research, PLLC, Idaho Falls, Idaho
Conditions: RSV Immunisation
Register for Updates
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
NCT05862272
Recruiting
The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis.
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
03/14/2024
Locations: Idaho Falls, Idaho Falls, Idaho
Conditions: Uterine Fibroids, Endometriosis
Register for Updates
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
NCT05584202
Recruiting
The study will evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in infants aged 12 weeks to < 6 months.
Gender:
All
Ages:
Between 2 months and 6 months
Trial Updated:
03/12/2024
Locations: Medical Research Partners- Ammon, Ammon, Idaho
Conditions: SARS-CoV-2
Register for Updates
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
03/11/2024
Locations: Research Site, Boise, Idaho
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Register for Updates
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
NCT03887715
Recruiting
Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale assessment tools at 12 months from randomization.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Pearl Health Clinic, Ammon, Idaho
Conditions: Treatment Resistant Depression
Register for Updates
Intravesical BCG vs GEMDOCE in NMIBC
NCT05538663
Recruiting
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival (EFS) compared to standard treatment with intravesical BCG. The purpose of this study is to test whether Gemcitabine + Docetaxel is a better or worse treatment than the usual BCG therapy approach. The primary objective of this study is to determine the event free survival (EFS) of BCG-naïve high gr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Conditions: Non-muscle-invasive Bladder Cancer
Register for Updates